# Immunogenicity and Safety Study of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine in 2-71 Months Old Healthy Infants and Toddlers (the Youngest Could be 6 Weeks Old)

> **NCT02736240** · PHASE3 · COMPLETED · sponsor: **Walvax Biotechnology Co., Ltd.** · enrollment: 2760 (actual)

## Conditions studied

- Diseases Caused by Streptococcus Pneumoniae Serotypes

## Interventions

- **BIOLOGICAL:** 7-valent pneumococcal conjugate vaccine
- **BIOLOGICAL:** 13-valent pneumococcal polysaccharide conjugate vaccine

## Key facts

- **NCT ID:** NCT02736240
- **Lead sponsor:** Walvax Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-08
- **Primary completion:** 2017-12-03
- **Final completion:** 2017-12-03
- **Target enrollment:** 2760 (ACTUAL)
- **Last updated:** 2020-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02736240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02736240, "Immunogenicity and Safety Study of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine in 2-71 Months Old Healthy Infants and Toddlers (the Youngest Could be 6 Weeks Old)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02736240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*